SCHEMBL1780575

SCHEMBL1780575

Cn1nc(N2CCNC(=O)C2)c(=O)n(C)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.43
▸ OPRM1 P35372 2/20 0.37
▸ OPRK1 P41145 2/20 0.37
▸ OGFRL1 Q5TC84 2/20 0.37
▸ OPRD1 P41143 1/20 0.37
▸ PRKCH P24723 1/20 0.37
▸ PRKCE Q02156 1/20 0.37
▸ TOP2A P11388 1/20 0.34
▸ TOP2B Q02880 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ FAP Q12884 2/20 0.33
▸ PRMT5 O14744 1/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK4 P11802 1/20 0.32
▸ CCND1 P24385 1/20 0.32
▸ CCND3 P30281 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ CDK6 Q00534 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781299 0.80 DPP4 (0.41) TSHRDPP4
SCHEMBL1782924 0.74 BRPF1 (0.36) —
SCHEMBL15330917 0.65 HTT (0.37) KDM4EPRKCHPRKCETOP2ATOP2B
SCHEMBL10094631 0.65 HSD11B1 (0.46) KDM4EPRKCHPRKCEPIK3CAMTOR
SCHEMBL1923288 0.64 DCTPP1 (0.53) MAPTTSHR
SCHEMBL30719385 0.64 KDM4E (0.43) KDM4EOPRM1OPRK1OGFRL1OPRD1
SCHEMBL85702 0.63 — —
SCHEMBL17847543 0.63 HTR2C (0.67) KDM4EOPRM1OPRK1OGFRL1OPRD1
SCHEMBL15055212 0.62 HTR3E (0.53) OPRM1PIK3CAMAPTTSHR
SCHEMBL20953955 0.62 KDM4E (0.55) KDM4EOPRM1PRKCHPRKCEPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328886-B1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PF MEDICAMENT (FR) 2016-12-28 — — EP disclosed
US-8618287-B2 Derivatives of triazines and uracils, their preparation and their application in human therapeutics PIERRE FABRE MEDICAMENT (FR) 2013-12-31 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2011-05-19 — — US disclosed
WO-2010006962-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS PIERRE FABRE MEDICAMENT (FR) 2010-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118266-A1 DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS UNG, TYMS, UMPS KDM4E 2189/4885OPRM1 134/4885OPRK1 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback